MedTrace Logo

To Evaluate The Efficacy And Safety Of Sunpharma1505 Compared With Reference1505 In Subjects With Active Rheumatoid Arthritis

NCT02534896 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2021-11-19

Study results available
· View outcomes & findings →

Summary

This study is designated to evaluate the safety and efficacy of Sunpharma1505 in subjects with active rheumatoid arthritis who are experiencing a flare/exacerbation.

Conditions

  • Active Rheumatoid Arthritis

Interventions

DRUG

Treatment I

Sunpharma1505 and Placebo

DRUG

Treatment II

Sunpharma1505 and Placebo

DRUG

Treatment III

Reference1505 and Placebo

Sponsors & Collaborators

  • Sun Pharmaceutical Industries Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2018-03-31
Completion
2018-06-30

Countries

  • Belgium
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02534896 on ClinicalTrials.gov